prostate cancer
Conditions
Interventions
None listed
Sponsors
Matsuyama Red Cross Hospital
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: Patients must meet all of the inclusion criteria from 1 to 4 below and caregivers must meet the inclusion criterion 5 in order to be eligible to participate in the study. 1. Prostate cancer outpatients who have visited Matsuyama Red Cross Hospital Urology Department more than once 2. Prescribed six-month depot formulation 3. Agree to participate in the study 4. Eligible to read, understand, and answer the questionnaire for patients 5. Caregiver of patient who meet the inclusion criteria above who agree to participate in the study
Exclusion criteria
Exclusion criteria: 1. Patients who have never prescribed luteinizing hormone-releasing hormone (LH-RH) agonist/LH-RH antagonist luteinizing hormone-releasing hormone (LH-RH) agonist/LH-RH antagonist 2. Caregivers of patients who cannot agree to participate in the study 3. Investigators, near relatives of investigators, investigator assistant, or near relatives of investigator assistant. 4. Who were judged clinically that responses to the questionnaire are improper or unsuitable by the principal investigator or collaborating physicians. 5. Who reject the participation of the study 6. Who wish to withdraw after the consent 7. When a false entry is identified
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To consider preferences of prostate cancer patients prescribed six-month depot formulation of Leuprorelin acetate injection and their caregivers, amongst 4 week depot (one-month depot formulation), 12 week depot formulation (three-month depot formulation), and six-month depot formulation, focusing on the following groups. - Patients who have difficulty visiting hospitals - Patients with high caregiver burden - Patients who change planned hospital visits frequently - Patients with multiple comorbidities at start of treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| To add consideration on the relationship between patient preference of six-month depot formulations and the following factors: reduction of the frequency of painful injections, reduction of annual medical expenses for prostate cancer treatment, reduction of the frequency of hospital visits, reduction of the burden of the caregiver, reduction of the frequency of consultations with the doctor, reduction of the time of stay at the hospital, improvement of the quality of life. To consider burdens of caregivers and preference of six-month depot formulations. | — |
Countries
Japan
Contacts
Public ContactAkira Yano, M.D., Ph.D.
Matsuyama Red Cross Hospital Department of Urology
Outcome results
None listed